Astal Labs Authorizes Acquisition Discussions & ₹300 Cr Fundraising

Astal Laboratories Ltd announced outcomes from its board meeting held on June 29, 2026. The board has authorized Mr. Sudheer Karna Kankanala, Whole-time Director, to explore and negotiate the acquisition of USFDA/EU-GMP/WHO-GMP compliant pharmaceutical manufacturing units in India. This strategic move aims to expand manufacturing capacity and strengthen global market presence. Additionally, Mr. Balayogiswara Rao Peddinti, CFO, is authorized to raise up to ₹300 Crore through various convertible and non-convertible instruments via private placement, subject to approvals. The meeting commenced at 10:00 AM and concluded at 10:48 AM.